Received-SPF: Pass (protection.outlook.com: domain of hra.nhs.uk designates
 2a01:111:f403:c205::3 as permitted sender) receiver=protection.outlook.com;
 client-ip=2a01:111:f403:c205::3;
 helo=LO2P265CU024.outbound.protection.outlook.com; pr=C
From: no-reply-IRAS <no-reply-iras@hra.nhs.uk>
To: "sis@warwick.ac.uk" <sis@warwick.ac.uk>
Subject: IRAS 316755. Amendment
Thread-Topic: IRAS 316755. Amendment
Thread-Index: AQHcsHQP32I18c2xHEuvH/94ebYuug==
Date: Tue, 10 Mar 2026 09:55:44 +0000
Message-ID: <LO0P302MB0209B0AFEC35D72FC5FFD4339046A@LO0P302MB0209.GBRP302.PROD.OUTLOOK.COM>
Accept-Language: en-GB, en-US
Content-Language: en-US
Authentication-Results-Original: dkim=none (message not signed)
 header.d=none;dmarc=none action=none header.from=hra.nhs.uk;
X-Microsoft-Antispam-Message-Info-Original: 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
X-Forefront-Antispam-Report-Untrusted: CIP:255.255.255.255;CTRY:;LANG:en;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:LO0P302MB0209.GBRP302.PROD.OUTLOOK.COM;PTR:;CAT:NONE;SFS:(13230040)(19092799006)(1800799024)(366016)(376014)(38070700021)(8096899003);DIR:OUT;SFP:1101;
X-MS-Exchange-AntiSpam-MessageData-Original-ChunkCount: 1
X-MS-Exchange-AntiSpam-MessageData-Original-0: =?us-ascii?Q?8qEO8tRr0CGuh6M9/RfbL+z5LteQJuUR1K5YSVRYyfxDdqnDqBpayZlPmMDS?=
 =?us-ascii?Q?uK7duFsL7zcF3oFH5AXPHRtjbEdmesJlIVnWVsvJz9tJi9z3GZCKegb5Y1m1?=
 =?us-ascii?Q?v7x/82tT76gSVcgr74qg2IXGuEMg/dHta3i3f4KNTeKMIWHpoelrvX5zz5d2?=
 =?us-ascii?Q?9n+ct6Cm/4XogehVgh9PFNvHh9YrUF+cdAsMRqgMlJ7vMnaD0Q3Ja3ZkvO0M?=
 =?us-ascii?Q?WXRPmRt/lfN3ZLlZb8VSZwqIkScX6LAHEzP6oqi6utnJEeeo/sNxYFvkbIRv?=
 =?us-ascii?Q?kW4uQvMAd86zEygk/rURDI9FLv+JOUc6vVcGYUSqLMfHberj0BWgOeN0HI2C?=
 =?us-ascii?Q?NFMcQD4FYs6ZnTyWJ89/7kqQs5ooF/GgFfjsIG+X1hI90wKW1GioURllNqFZ?=
 =?us-ascii?Q?JIoMR/bIfO8N6mhksufO0ZSIR05CtkzRXp+zQZ+yH7bBEfxssawWdnAkNGC/?=
 =?us-ascii?Q?+5uSzEjDlurzKLrQKk3w/AsCsThNVJGX4VJbJxS0RbN/G25GciLJSk02qIM6?=
 =?us-ascii?Q?W0rHxohg+WnKgYsMIT4DJDd7F1oDBTqySnZHcrJiC6CDcB05a1IGUJB7qsFP?=
 =?us-ascii?Q?/TZb29VwZTXA+Zj+tluLQKQOsdG3j3wuaQtZngQY/FsSokXIP8mDK3WoAi0U?=
 =?us-ascii?Q?RZ+k0QDXo0BoqGok410XKOvS69L3OpqUem+U1Xm5xYFUxAc7ggYyu+O4yXPp?=
 =?us-ascii?Q?Qy7d8FKhSClpULSriB9p+7JVWpjK7ZagHbHhHLZNXjpGdGYSkp7Tu8ug8ibW?=
 =?us-ascii?Q?dMx6iG3P47xBo4pdGnGOb7dXGQe0PofmshQ3a3zsM9hVYJvXZR/gAojg/X5M?=
 =?us-ascii?Q?DKo0QusyZqwpMyx/L3mRynKGGUS8tyTm+G2rV2Im2YnL4mM9WpMO8mYHJ4KB?=
 =?us-ascii?Q?5+GMzXsL2AvD6OPwEoz/kqRd3S/9d+Hgyg2jRLWxsOm98MSSaQZFTdkKNfd1?=
 =?us-ascii?Q?vZGmoNlW2oBo5FAB6yZQW9hQa3cXaISaKo+Ek0YC0N6cluOpr1U7FmBWAQmZ?=
 =?us-ascii?Q?5lPuAAVMp8owATc4OcLit8HW4WyjkP5wzEVpI6u5F7rlpFKUtbxUQ/eyXqat?=
 =?us-ascii?Q?RAO671l1VBdZsDM1WIVB3f7j8MXTIwNIe4SbNUbAzdsnrrNFucpmgstJMN3E?=
 =?us-ascii?Q?UZo53nrs6T0BYH+19frGTGgZTZgsJ9oXgtPiCC0fgPwc3L6y86IaAbOWqwLi?=
 =?us-ascii?Q?JlibqyB66rIvGfLR8N66YoE1z0/wFZWwRtRrKYwP6gJrsJCASxzfkU2/GmjV?=
 =?us-ascii?Q?FI/ippmVRMYJAHXCOBVmfVyPd4dUFjzJB1t+zkvDvJcN0ANkUolzWfKgK2yf?=
 =?us-ascii?Q?bYWhOkdVA6iXP9xF6E8VZmGBw88DWXJ8NlhSadqoYHYjrEWFfPtdfBtt9F/N?=
 =?us-ascii?Q?GHo1fX1boDykoibkbl/oRTtUIcMWSxatX5xmmADfAfHtPtb6gRtA9v7YReUg?=
 =?us-ascii?Q?/sF8gh9QIAEjrRNefupC7eMkkBIXMeLII1xTBlejESEXjm1viXC6ixiH1und?=
 =?us-ascii?Q?b6O1GZUxjfr8nB/o6RZRDgzywworzenpkSLcx8gIn4wITOiykRPS9s3IKB6w?=
 =?us-ascii?Q?svoBEBeZ0YXlNNOFV5FhbEPxjDG/FqChC1dS4gcitUI1YGYe1EPRP+7Xh1O2?=
 =?us-ascii?Q?v1AiNYgHDUxWwnYVYEYfh4IuROmN6FO9/MKh6aZJZ9K645Z5FHWWfCsSQPC+?=
 =?us-ascii?Q?dPfJj4Oxc3yrvje1Yvey9v17tT4/0SMpJzIDDWn3Mfb4KWpvN4btxUDQxODI?=
 =?us-ascii?Q?5I+vV27veb7VeRSVsQQjwZQ05sQI0j4=3D?=
Content-Type: multipart/alternative;
	boundary="_000_LO0P302MB0209B0AFEC35D72FC5FFD4339046ALO0P302MB0209GBRP_"
X-MS-Exchange-Transport-CrossTenantHeadersStamped: LO0P302MB1757
Return-Path: no-reply-iras@hra.nhs.uk
X-MS-Exchange-Organization-ExpirationStartTime: 10 Mar 2026 09:55:46.6752
 (UTC)
X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit
X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000
X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit
X-MS-Exchange-Organization-Network-Message-Id: dc66b102-9a97-421e-c745-08de7e8b33bc
X-EOPAttributedMessage: 0
X-EOPTenantAttributedMessage: 09bacfbd-47ef-4465-9265-3546f2eaf6bc:0
X-MS-Exchange-Organization-MessageDirectionality: Incoming
X-MS-Exchange-Transport-CrossTenantHeadersStripped: AM4PEPF00027A62.eurprd04.prod.outlook.com
X-MS-Exchange-Transport-CrossTenantHeadersPromoted: AM4PEPF00027A62.eurprd04.prod.outlook.com
X-MS-PublicTrafficType: Email
X-MS-Exchange-Organization-AuthSource: AM4PEPF00027A62.eurprd04.prod.outlook.com
X-MS-Exchange-Organization-AuthAs: Anonymous
X-MS-Office365-Filtering-Correlation-Id-Prvs: 8796b36e-c3ca-4199-c573-08de7e8b3236
X-MS-Exchange-AtpMessageProperties: SA|SL
X-MS-Exchange-Organization-SCL: 1
X-Microsoft-Antispam: BCL:0;ARA:13230040|35042699022|12012899012|8096899003|54012099003;
X-Forefront-Antispam-Report: CIP:2a01:111:f403:c205::3;CTRY:;LANG:en;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:LO2P265CU024.outbound.protection.outlook.com;PTR:mail-uksouthazlp170110003.outbound.protection.outlook.com;CAT:NONE;SFS:(13230040)(35042699022)(12012899012)(8096899003)(54012099003);DIR:INB;
X-MS-Exchange-CrossTenant-OriginalArrivalTime: 10 Mar 2026 09:55:46.6121
 (UTC)
X-MS-Exchange-CrossTenant-Network-Message-Id: dc66b102-9a97-421e-c745-08de7e8b33bc
X-MS-Exchange-CrossTenant-Id: 09bacfbd-47ef-4465-9265-3546f2eaf6bc
X-MS-Exchange-CrossTenant-AuthSource: AM4PEPF00027A62.eurprd04.prod.outlook.com
X-MS-Exchange-CrossTenant-AuthAs: Anonymous
X-MS-Exchange-CrossTenant-FromEntityHeader: Internet
X-MS-Exchange-Transport-CrossTenantHeadersStamped: VE1PR01MB12340
X-MS-Exchange-Processed-By-BccFoldering: 15.20.9678.017
X-Microsoft-Antispam-Mailbox-Delivery:
	ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(930201)(20251009189)(140003)(1420198);
X-Microsoft-Antispam-Message-Info:
	=?us-ascii?Q?R/peK63VsK51rHnkN/6MPSz5pS6yqHKynCPo6QHiYRacPGAJzA3E7U1ui6BR?=
 =?us-ascii?Q?Qfs+A6TfUwyoC6URFcVfS1khBr82g/co7elDgwRBF5l9z3MqP1FXegPkgdIY?=
 =?us-ascii?Q?DM+YjXZeeznPpRHvjP7SzthjUfyNljTW55gj2HNY/v2QaQJfEvKN0PKpnt8S?=
 =?us-ascii?Q?Cxmrr2cwcN5FrM/ZFl0w3H/Xies0mBHFaYNXPR0bwn3lWN+juXDYSJexQCMH?=
 =?us-ascii?Q?kad+fV1l0kH+Db+Kw80DbldFS2cnMWwMdSuYHB5jfUyhhCvNevuhhkCAraO0?=
 =?us-ascii?Q?U9mUCgNg2uu3x7BHXh1TmyRB47VZPDFf/uqq3pMzItDY31pmdziEnELKOs0g?=
 =?us-ascii?Q?fg+b0a7jqY0eufkIPVpVtNIpqaMqGOEXFjZpZ9Y4NhDfj2Itt7afXUIOVDJO?=
 =?us-ascii?Q?PQU2yoz1U+rj1JQR9Q+4/rkfxjM7dUunMUZ5W4lCwnA/8T8MjaeD/0k8K2XL?=
 =?us-ascii?Q?JEKRy5LCJY4KH5vVZqFtB0YZhBwUNVHaaE2Ju6Rv0oR7asj3KEQf0y3ZyvZy?=
 =?us-ascii?Q?tWLmsvzdwLeIIibxwLzpvKa39iABEv3U1yWAZJsAiPFKXxxJdsBoPGcPG0Zc?=
 =?us-ascii?Q?yOO8SdHFJaM6O9gYyuroMqHo/wnR4I9CJmLbHYmlI8BAFNkYP/q0vGyMrIaQ?=
 =?us-ascii?Q?fOHG44FytlMhE3AWroen9q/FFC4Ta8JEsWFbPUTprAKtlZERsVmmvarBWWTd?=
 =?us-ascii?Q?hjBePWVrVC088r3aKst3FH+s9C1D6NxYq6pgvQZLXOyo3cRuA69jnm7nm1RG?=
 =?us-ascii?Q?QQSki7x6NhY755leZmcLnXQpkm+AQ3+45m6BQl0fSFg+ogrga1Md3ksWj3aw?=
 =?us-ascii?Q?C0Hn50f7lqYdApWKS1SES8F61zKgBJj1Wd3drMazYhU1nCwqfOvaPb7ybCWq?=
 =?us-ascii?Q?3Qaii5q/+kkIBW5t/Y91LMlGI8y8AmzllJHIRMaYp2/QE7zcay07v/RtJbMP?=
 =?us-ascii?Q?tsp5aNGQrloiSS34S5CPTAdZTid6EKiRPS/b3nh2j4j9uyG3FnYeGeJQbelh?=
 =?us-ascii?Q?vBhVyS5+XX57zl+Y+qOKVKIbU5+b/Fd5UVGk15xD8LhgM5+Cv8qWUSKKLC+x?=
 =?us-ascii?Q?6BOlw7bwg+xi6dFi3KZoWj+3U+KWmlfn8G6DV9FdAemMJR5D+1mHp3NOfOlB?=
 =?us-ascii?Q?Hq3KnFckjqL5lHTVTuqeuPWPLHpIHSMAJ7IG2dcjJvxUgqQ+PEBllhaCmB/H?=
 =?us-ascii?Q?E+2FEQ4QPSubUH639A8a0EvAjeYv/VjgRX42YSINBUt2dqZr9WmDhI9sCU1h?=
 =?us-ascii?Q?R6o5l7mtBMNFJoUawOn6H0kiFxjGOjP73ahlm9J2NdIpZu6VdqAYyRpI0p/3?=
 =?us-ascii?Q?xNaZERJ9lre9iqE8NQYeot58BtG3KqyS5TOdWg5PSxSB+Jitdyc3Lw0y+art?=
 =?us-ascii?Q?lTZosP1ICBiTwV09HT9sim6l77aYUTc+e9vNlv0GpTEGxcjvOrFgQeNUH+Wt?=
 =?us-ascii?Q?UuAGWqHuINBmde8SFVpUuIQvd2ERTGpmjtqGiceIMBKf6IxNcB9crJahRzfF?=
 =?us-ascii?Q?D/7eIHpUozCwDgc/QiXeb/QXk8A86YGbX07kGB0oq0PBtuDq5rjPby3BGxpa?=
 =?us-ascii?Q?xbzD6QZzOWmc7U5tlFYxmTpxbyTIRqQxfSZWzpqD7ia2MtqyViRL4tiqtJhG?=
 =?us-ascii?Q?Dt23HPh4u0VVTmahjjPHA2CtLVOaoOBfIwpBWzh/YLbCI5kta9v7nCosAddt?=
 =?us-ascii?Q?BSkaNGjy4Ma37mZtxB9PDWvsVppzsA3vj1sO8f3P3PsIc5py8VDoMTdxwcV4?=
 =?us-ascii?Q?R4vXXG4+FQs4b8zRiNM0TPt9b9Ax7nrdsyVVN8qfdtL3s7k5t4VzNDZ/DoMy?=
 =?us-ascii?Q?pU6h7LEmCDIcXU2TyF8yEanOAbOXq8qBIhok3V5OuLBEQNNEkEBV+E44nUSO?=
 =?us-ascii?Q?MbPWIx49mz7i7UvAhpRxw5xaVlG4YB/QN9NqBJnAt6PmVjqQvIOLKjjRaFqE?=
 =?us-ascii?Q?+RhowlzF5XPHuyTJ1+zbqswoqMg023SAWbW6/0uRSRxbvSZporT8XIFd0sKJ?=
 =?us-ascii?Q?/a6b0R55eBF7DA0PV/0R26dXm1Cc4RHICGxpFy//8anvhcXnI8YhZTxw6XFA?=
 =?us-ascii?Q?7UZDwiyyy5W0wUAYWJ2ghSTLNNY5ygM1fgoAsiB6eBHT/5dnYnLE3pPdgJxa?=
 =?us-ascii?Q?X79Ta6zwc+T7pu1DWv2OS6mzrurhtVHjPzOLXln0zb/B+DBLDyk9tCDbQqd4?=
 =?us-ascii?Q?/YQ07zUTpDgY0TiBWgv3Cj1x1tV/MeiO25zkbDq2aki/ZZ9NYxJJRxiss1xY?=
 =?us-ascii?Q?+R/BUJi9gmjWQVAJKoRTbN2RCkLqocjw+htLWVLTZzTUw12yy5fClGz1OEls?=
 =?us-ascii?Q?2srRF0N9wvKElCETEp0IpieWAwdD60hmpyF9FOaFj6T5r9JIarvmw6oEDDm2?=
 =?us-ascii?Q?C56A7gUeJfqU1PfteaazqjpA/DRicYHAzVdGAjO+xpuFyTxy/SKAQPubPWz8?=
 =?us-ascii?Q?IPfRnC9bk5Q7V8WnziRa59YFyG5sDdTYPAV0x8YG1h7knhQpkFCDyW67iDq2?=
 =?us-ascii?Q?MXgW/jJN93xp/8LBPtNiBMR7kWnFtup3K+JAhOtFZEn2qP+K7u9OBU0q8ZHn?=
 =?us-ascii?Q?k+h0kDwLmsUl2Rs09sZU1JLMiGKp/MITVV1AZzRDnNvRnO4lkBQl7mbnVBP+?=
 =?us-ascii?Q?m5xg4o2q8oK8m+CVwqnC1lLO+2XqT0PDzR8tgmNZ8ktjD22GOa9oAbRzpXTg?=
 =?us-ascii?Q?6lWE5mMNbhP5pM2986qqFVBGYUPs+df1PDxSF3sW2vD0YT7jNhyYd/ASw6FW?=
 =?us-ascii?Q?oo4MGp2WCfZ8TNi62yFj60W2sBBc7I8PwtBRvGJR8c4xMzdAgGygDdvhdR7B?=
 =?us-ascii?Q?2imm2Uli2t35ue7sYF4KfhrVT6HBI8JWwgzLAX16wTapAPqlUkTCoLdiGOPT?=
 =?us-ascii?Q?DiHKas5cj8DefRphKd9W2Bkix2nxi4qMob+Adzz4OBwn6Rq9m4kQtjE6G7vI?=
 =?us-ascii?Q?Z48IZF4kws39KHHikdqWQFUqzO1KMlpRztjTeyLaLsP+JLvEPyoDEOnM+MLb?=
 =?us-ascii?Q?VvX6XC+gA2v72MCfic9B502e9t81Fgv2I9ZQYGIjaXgpelY=3D?=
MIME-Version: 1.0

--_000_LO0P302MB0209B0AFEC35D72FC5FFD4339046ALO0P302MB0209GBRP_
Content-Type: text/plain; charset="us-ascii"
Content-Transfer-Encoding: quoted-printable


IRAS Project ID:                            316755
Sponsor amendment reference: NSA24


Thank you for submitting your study amendment.  In accordance with the outc=
ome of your completed amendment tool, this amendment requires no further re=
gulatory review. Please now share this amendment with your UK research site=
s, in accordance with the instructions in your completed amendment tool.

For studies with more than one UK research site, your amendment will now be=
 automatically shared with the R&D offices of any NHS/HSC research sites in=
 Scotland, but you should share the amendment by email directly with those =
Research team/s.

For all NHS research sites in England, Wales and Northern Ireland, please n=
ow share this amendment by email directly with those sites, including both =
the R&D offices and research teams.

Do not reply to this email as this is an unmonitored address and replies to=
 this email cannot be responded to or read.

________________________________
This message may contain confidential information. If you are not the inten=
ded recipient please inform the sender that you have received the message i=
n error before deleting it. Please do not disclose, copy or distribute info=
rmation in this e-mail or take any action in relation to its contents. To d=
o so is strictly prohibited and may be unlawful. Thank you for your co-oper=
ation..
________________________________

--_000_LO0P302MB0209B0AFEC35D72FC5FFD4339046ALO0P302MB0209GBRP_
Content-Type: text/html; charset="us-ascii"
Content-Transfer-Encoding: quoted-printable

<!DOCTYPE html><html><head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3Dus-ascii"=
>
<title>IRAS 316755. Amendment</title>
</head>
<body>
<p style=3D"margin:0cm 0cm 8pt"><br>
<strong>IRAS Project ID:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &n=
bsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong> 316755 &nbsp;<br>
<b>Sponsor amendment reference:&nbsp;</b>NSA24&nbsp;<br>
<br>
<br>
<span style=3D"font-size:14px;"><span style=3D"font-family:Arial,Helvetica,=
sans-serif;"><span style=3D"line-height:normal"><span lang=3D"EN-GB">Thank =
you for submitting your study amendment.&nbsp; In accordance with the outco=
me of your completed amendment tool, this amendment
 requires no further regulatory review.&nbsp;Please now share this amendmen=
t with your UK research sites, in accordance with the instructions in your =
completed amendment tool.</span></span><br>
<br>
<span lang=3D"EN-GB"><span style=3D"line-height:107%">For studies with more=
 than one UK research site, your amendment will now be automatically shared=
 with the R&amp;D offices of any NHS/HSC research sites in Scotland, but yo=
u should share the amendment by email directly
 with those Research team/s.</span></span><br>
<br>
<span style=3D"line-height:normal"><span lang=3D"EN-GB">For all NHS researc=
h sites in England, Wales and Northern Ireland, please now share this amend=
ment by email directly with those sites, including both the R&amp;D offices=
 and research teams.</span></span><br>
<br>
<span lang=3D"EN-GB"><span style=3D"line-height:107%">Do not reply to this =
email as this is an unmonitored address and replies to this email cannot be=
 responded to or read.</span></span></span></span></p>
<hr>
This message may contain confidential information. If you are not the inten=
ded recipient please inform the sender that you have received the message i=
n error before deleting it. Please do not disclose, copy or distribute info=
rmation in this e-mail or take any
 action in relation to its contents. To do so is strictly prohibited and ma=
y be unlawful. Thank you for your co-operation..
<hr>
</body>
</html>

--_000_LO0P302MB0209B0AFEC35D72FC5FFD4339046ALO0P302MB0209GBRP_--